Andrew Richard Novak

This inventor holds 20 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 14 EPO patents, primarily in GLP-1 Receptor Modulators. Top assignees: Celgene International Ii Sarl, Receptos, Inc., Step Pharma S.a.s.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Richard Novak. Retrieved from https://idiyas.com/inventor/andrew-richard-novak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 4)

% Patents Active = 80.0

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 14 (Patent Applications = 10)

Average Co-Inventor Count = 6.5

ph-index = 8

Forward Citations = 111(Granted Patents)

Location History:

Long Eaton, GB (2014 - 2019)
Nottingham, GB (2013 - 2023)

Company Filing History:

7 out of 17

Celgene International Ii Sarl

Kalvista Pharmaceuticals Limited

patents

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Aminothiazole Compounds

CTPS1 Inhibitors

Plasma Kallikrein

GLP-1 Receptor Modulators

GLP-1 Receptor Stabilizers

Heterocyclic Derivates

Inhibitors

Compounds

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12503466 - Aminothiazole Compounds as Inhibitors of CTPS1 (2025-12-23),

2. 12319680 - Compounds (2025-06-03),

3. 11655246 - Aminothiazole compounds as inhibitors of CTPS1 (2023-05-23),

4. 11505547 - Compounds (2022-11-22),

5. 11242333 - Inhibitors of plasma kallikrein (2022-02-08),

6. 10259823 - GLP-1 receptor modulators (2019-04-16),

7. 10221161 - Inhibitors of plasma kallikrein (2019-03-05),

8. 10034886 - GLP-1 receptor modulators (2018-07-31),

9. 9839664 - GLP-1 receptor modulators (2017-12-12),

10. 9795613 - GLP-1 receptor modulators (2017-10-24),

11. 9700543 - GLP-1 receptor stabilizers and modulators (2017-07-11),

12. 9598430 - GLP-1 receptor modulators (2017-03-21),

13. 9533987 - Heterocyclic derivates (2017-01-03),

14. 9474755 - GLP-1 receptor modulators (2016-10-25),

15. 9278910 - GLP-1 receptor stabilizers and modulators (2016-03-08),

Title: Unveiling the Inventive Journey of Andrew Richard Novak

Introduction:

Andrew Richard Novak is a prolific inventor hailing from Nottingham, GB, with an impressive portfolio of 18 patents to his name. His groundbreaking work has significantly contributed to the field of pharmaceuticals, particularly in the area of aminothiazole compounds as inhibitors of CTPS1.

Latest Patents:

Novak's latest patents delve into aminothiazole compounds as inhibitors of CTPS1, showcasing his expertise in developing Compounds of formula (I) and related aspects. These compounds have the potential to revolutionize the landscape of pharmaceutical interventions.

Career Highlights:

Throughout his career, Andrew Richard Novak has lent his innovative prowess to esteemed companies such as Celgene International II Sàrl and Receptos, Inc. His tenure in these organizations has been marked by a relentless pursuit of excellence in pharmaceutical research and development.

Collaborations:

In his quest for innovation, Novak has collaborated closely with notable individuals in the industry, including Premji Meghani and Marcus F Boehm. These collaborations have not only enriched his own work but have also paved the way for groundbreaking discoveries in the realm of aminothiazole compounds.

Conclusion:

Andrew Richard Novak's unwavering dedication to innovation and his keen insight into pharmaceutical research have solidified his position as a trailblazer in the field. His patents stand as a testament to his inventive spirit and his enduring legacy in shaping the future of pharmaceutical interventions.

Profile summary based on public USPTO records.